Hormone Therapy News

More women are turning to complementary and alternative medicine to treat their menopausal symptoms without first consulting a clinician, according to research in Menopause, and a leading menopause group is calling on clinicians to take a more active role in educating patients about the various therapies.

Boys with idiopathic short stature are two to three times more likely to receive growth hormone treatment than girls, despite sex not playing a role in the condition, according to research in Scientific Reports.

The North American Menopause Society has formally recommended that hormone therapy be considered for women over age 65 years, citing recent research on longer-lasting menopausal symptoms and a lack of effective treatment alternatives.

In an 18-to-6 vote at the FDA joint meeting of the Bone, Reproductive and Urologic Drugs Advisory Committee, and the Drug Safety and Risk Management Advisory Committee, flibanserin was recommended for approval to treat hypoactive sexual desire disorder in premenopausal women.

Hormone therapy in younger postmenopausal women does not increase the risk for cognitive decline and may lead to beneficial mood effects, according to research in PLOS Medicine.

Growth hormone dosing in children with Prader-Willi syndrome may be appropriately indicated by immunoreactive insulin-like growth factor I, according to recent study findings published in The Journal of Clinical Endocrinology & Metabolism.

Changes in ovarian estradiol secretion may lead to abnormal behavior among postmenopausal women with past perimenopausal depression who previously received hormone therapy, according to results from a randomized, double-blind, placebo-controlled trial.

NASHVILLE, Tenn. — Hypophosphatemic rickets, tumor-induced osteomalacia and chronic kidney disease may at first appear different from one another, yet they share a common thread — fibroblast growth factor 23, known as FGF23, plays an important role in all three.

NASHVILLE, Tenn. — Use of the intravenous bisphosphonate pamidronate to prevent bone resorption was associated with improved mortality, ventilator discontinuation and renal parameters in patients with chronic critical illness, according to data presented here.

NASHVILLE, Tenn. — Daily oral testosterone did not significantly increase biomarkers of cardiovascular risk in hypogonadal men, compared with transdermal testosterone, according to data presented here.